Despite efforts for improvement, the "State of the Air" report reveals concerns.

Published Date: 23 Apr 2023

Despite Improvement Efforts, the "State of the Air" Report Highlights Issues.

Read Full News

Latest News

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

Todays Updates

Phase 2 ACUITY Analysis Shows Privosegtor Associated With Smaller Early NfL and GFAP Increases in Acute Optic Neuritis Isabella Ciccone, MPH

New biomarker data showed smaller post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein with privosegtor added to steroids in patients with acute optic neuritis.

CORE-VNS Study Shows Sustained Seizure Reduction With VNS Therapy at 36 Months Louie Pasculli

The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.

The Expanding Role of Blood-Based Biomarkers in MS Care Louie Pasculli, Terrie Livingston, PharmD

Terry Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Todays Updates

Phase 2 ACUITY Analysis Shows Privosegtor Associated With Smaller Early NfL and GFAP Increases in Acute Optic Neuritis Isabella Ciccone, MPH

New biomarker data showed smaller post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein with privosegtor added to steroids in patients with acute optic neuritis.

CORE-VNS Study Shows Sustained Seizure Reduction With VNS Therapy at 36 Months Louie Pasculli

The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.

The Expanding Role of Blood-Based Biomarkers in MS Care Louie Pasculli, Terrie Livingston, PharmD

Terry Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Latest News

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

News All Time

CHEST 2026: Day 3 Recap — 6 Headlines to Know

CHEST 2026: Day 3 Recap — 6 Headlines to Know

Why Oxygen Stigma Persists, With Mike Hess, MPH Mike Hess, MPH

On World Oxygen Day, the COPD Foundation's Mike Hess outlines the stigma, training gaps, and Medicare barriers affecting patients on supplemental oxygen.

Lower Baseline FVC Linked to Better Sarcoidosis Treatment Response Vivienne Kahlmann

A post-hoc PREDMETH analysis presented at ERS 2026 links lower baseline FVC and shorter disease duration with greater FVC gains on first-line therapy.

When to Switch Biologics in Severe Asthma, With Florence Schleich, MD, PhD Florence Schleich, MD, PhD

Schleich says biologic switching in severe asthma should follow exacerbation phenotyping and discusses response predictors and standardized follow-up.

Q&A: Curcumin Lowers IL-17 in COPD, With Retno Ariza Soemarwoto, MD

Q&A: Curcumin Lowers IL-17 in COPD, With Retno Ariza Soemarwoto, MD

Vanzacaftor Regimen Lets Some Children With Cystic Fibrosis Stop PERT

Vanzacaftor Regimen Lets Some Children With Cystic Fibrosis Stop PERT

ENCORE: Early ALIS Cuts MACLD Recurrence, With Jakko Van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

van Ingen, of Radboud University Medical Center discusses data showing add-on ALIS improved durable culture conversion in newly diagnosed MAC lung disease.

ENCORE ALIS Data Could Reshape First-Line MACLD: Jakko van Ingen, MD, PhD Jakko Van Ingen, MD, PhD

van Ingen, of Radboud University Medical Center, discusses the ENCORE trial's patient-reported endpoint for ALIS in MAC lung disease.

Mepolizumab Cuts COPD Exacerbations Across Smoking Status: Claus Vogelmeier, MD Claus Vogelmeier, MD

Vogelmeier, of Philipps-University of Marburg discusses pooled data showing reduced COPD exacerbations, though most effectively in former smokers.

CHEST 2026: Day 2 Recap — 4 Headlines to Know

CHEST 2026: Day 2 Recap — 4 Headlines to Know

Short Telomeres Linked to UIP Pattern, Not Fibrosis Extent, in ILD

Short Telomeres Linked to UIP Pattern, Not Fibrosis Extent, in ILD

Examining the Oral Steroid Burden in Asthma and COPD

Examining the Oral Steroid Burden in Asthma and COPD

TRPA1 Antagonist Shows Delayed but Meaningful Effect on IPF Cough Marlies Wijsenbeen, MD, PhD

Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity Victoria Johnson

A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

Recommended News For You

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

New imaging technique identifies glioblastoma patients who would benefit from immunotherapy

FDA Expands Durvalumab Label to Operable Lung Cancer

To refute accusations that it failed to issue a cancer warning, Roundup's maker is asking lawmakers for assistance.

MRI-guided radiation therapy improves quality of life with fewer side effects in patients with localized cancer. JAMA

Researchers Challenge USPSTF's Lung Cancer Screening Criteria

Targeted Combination Shows Promise in Metastatic Kidney Cancer

Recommended Articles For You

Pharmacokinetic Effects of Plasma Protein Concentration Changes 

Landmark Medical Oncology Trials Redefining Early Breast Cancer Management 

Chloride Test in HCC: Diagnostic Utility, Prognostic Role, and Emerging Insights 

Guidance for Monitoring Iron Overload 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

On all CAR-T products, the FDA is calling for a new boxed warning.

2.

Video: Liver transplant for patients with advanced colorectal cancer

3.

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

4.

Healthcare AI, Meant to Save Money, Turns Out to Require a Lot of Expensive Humans

5.

Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer

1.

A Closer Look at Breast Cancer: Examining the Ultrasound Images

2.

RIBOTAC Therapy for Oncogenic RNA: A Paradigm Shift in Targeted Cancer Treatment

3.

Monitoring Delayed Toxicity of Antibody Therapies

4.

Emerging Therapies Through Immune-Engineered Blood Cell Manufacturing

5.

What You Need To Know About Secondary Polycythemia: Treatment & Symptoms

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

2.

Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

4.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot